The Certainty Framework for Assessing Real‐World Data in Studies of Medical Product Safety and Effectiveness

Clinical Pharmacology & Therapeutics
Volume 109, Issue 5 Pages: 1159-1362 May 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

 

Reviews – White Paper
The Certainty Framework for Assessing Real‐World Data in Studies of Medical Product Safety and Effectiveness
Noelle M. Cocoros, Peter Arlett, Nancy A. Dreyer, Chieko Ishiguro, Solomon Iyasu, Miriam Sturkenboom, Wei Zhou, Sengwee Toh
Pages: 1189-1196
First Published:10 September 2020
Abstract
A fundamental question in using real‐world data for clinical and regulatory decision making is: How certain must we be that the algorithm used to capture an exposure, outcome, cohort‐defining characteristic, or confounder is what we intend it to be? We provide a practical framework to help researchers and regulators assess and classify the fit‐for‐purposefulness of real‐world data by study variable for a range of data sources. The three levels of certainty (optimal, sufficient, and probable) must be considered in the context of each study variable, the specific question being studied, the study design, and the decision at hand.

Randomized Controlled Trials Versus Real World Evidence: Neither Magic

Clinical Pharmacology & Therapeutics
Volume 109, Issue 5 Pages: 1159-1362 May 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

 

Review – Open Access
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
Hans‐Georg Eichler, Francesco Pignatti, Brigitte Schwarzer‐Daum, Ana Hidalgo‐Simon, Irmgard Eichler
Peter Arlett. Anthony Humphreys, Spiros Vamvakas, Nikolai Brun, Guido Rasi
Pages: 1212-1218
First Published:16 October 2020
Abstract
Compared with drugs from the blockbuster era, recently authorized drugs and those expected in the future present a heterogenous mix of chemicals, biologicals, and cell and gene therapies, a sizable fraction being for rare diseases, and even individualized treatments or individualized combinations. The shift in the nature of products entails secular trends for the definitions of “drugs” and “target population” and for clinical use and evidence generation. We discuss that the lessons learned from evidence generation for 20th century medicines may have limited relevance for 21st century medicines. We explain why the future is not about randomized controlled trials (RCTs) vs. real‐world evidence (RWE) but RCTs and RWE—not just for the assessment of safety but also of effectiveness. Finally, we highlight that, in the era of precision medicine, we may not be able to reliably describe some small treatment effects—either by way of RCTs or RWE.

Public support for European cooperation in the procurement, stockpiling and distribution of medicines

The European Journal of Public Health
Volume 31, Issue 2, April 2021
https://academic.oup.com/eurpub/issue/31/2

 

Health services research
Public support for European cooperation in the procurement, stockpiling and distribution of medicines
Roel Beetsma, Brian Burgoon, Francesco Nicoli, Anniek de Ruijter, Frank Vandenbroucke
European Journal of Public Health, Volume 31, Issue 2, April 2021, Pages 253–258, https://doi.org/10.1093/eurpub/ckaa201
Conclusion
Joint procurement raises delicate questions with regard to its scope, the inclusion of cross-border solidarity and the delegation of decision-making, that explain reluctance toward joint procurement among political decision-makers. This research shows that there is considerable public support across different countries in favor of centralization, i.e. a large scope and solidarity in the allocation and delegation of decision-making.

Coverage rates against vaccine-preventable diseases among healthcare workers in Sicily (Italy)

The European Journal of Public Health
Volume 31, Issue 2, April 2021
https://academic.oup.com/eurpub/issue/31/2

 

Infectious disease
Coverage rates against vaccine-preventable diseases among healthcare workers in Sicily (Italy)
Caterina Ledda, Venerando Rapisarda, Helena C Maltezou, Eleonora Contrino, Arianna Conforto
European Journal of Public Health, Volume 31, Issue 1, February 2021, Page 56, https://doi.org/10.1093/eurpub/ckaa179

Intersex care in the United States and international standards of human rights

Global Public Health
Volume 16, Issue 5 (2021)
http://www.tandfonline.com/toc/rgph20/current

 

Special Issue: The Contested Global Politics of Pleasure and Danger: Sexuality, Gender, Health and Human Rights; Guest Editors: Carmen H. Logie, Amaya Perez-Brumer and Richard Parker
Article
Intersex care in the United States and international standards of human rights
Juan Carlos Jorge, Leidy Valerio-Pérez, Caleb Esteban & Ana Irma Rivera-Lassen
Pages: 679-691
Published online: 24 Dec 2019

The role of government agencies and other actors in influencing access to medicines in three East African countries

Health Policy and Planning
Volume 36, Issue 3, April 2021
https://academic.oup.com/heapol/issue/36/3

 

ORIGINAL ARTICLES
The role of government agencies and other actors in influencing access to medicines in three East African countries
Walter Denis Odoch, Yoswa Dambisya, Elizabeth Peacocke, Kristin Ingstad Sandberg, Berit Sofie Hustad Hembre
Health Policy and Planning, Volume 36, Issue 3, April 2021, Pages 312–321, https://doi.org/10.1093/heapol/czaa189

Remote data collection for public health research in a COVID-19 era: ethical implications, challenges and opportunities

Health Policy and Planning
Volume 36, Issue 3, April 2021
https://academic.oup.com/heapol/issue/36/3

 

COMMENTARIES
Remote data collection for public health research in a COVID-19 era: ethical implications, challenges and opportunities
B Hensen, C R S Mackworth-Young, M Simwinga, N Abdelmagid, J Banda
Health Policy and Planning, Volume 36, Issue 3, April 2021, Pages 360–368, https://doi.org/10.1093/heapol/czaa158

Disability inclusion in humanitarian action

Humanitarian Exchange Magazine
Number 78, October 2020
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

 

Disability inclusion in humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies’ lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a ‘participation revolution’, building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox’s Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide’s approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC’s Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD’s SADI approach.

Demand for longer quarantine period among common and uncommon COVID-19 infections: a scoping review

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 1 May 2021]

 

Demand for longer quarantine period among common and uncommon COVID-19 infections: a scoping review
Authors: Zhi-Yao Li, Yu Zhang, Liu-Qing Peng, Rong-Rong Gao, Jia-Rui Jing, Jia-Le Wang, Bin-Zhi Ren, Jian-Guo Xu and Tong Wang
Content type: Scoping Review
26 April 2021

Predictors of acceptance of COVID-19 vaccine among patients at a tertiary hospital in South-South Nigeria

International Journal of Community Medicine and Public Health
Vol 8, No 5 (2021) May 2021
https://www.ijcmph.com/index.php/ijcmph/issue/view/76

 

Original Research Articles
Predictors of acceptance of COVID-19 vaccine among patients at a tertiary hospital in South-South Nigeria
Dennis O. Allagoa, Peter Chibuzor Oriji, Ebiye S. Tekenah, Lukman Obagah, Chidiebere Njoku, Adeniyi Stephen Afolabi, Gordon Atemie
DOI: 10.18203/2394-6040.ijcmph20211733

Increasing vaccine acceptance using evidence-based approaches and policies: Insights from research on behavioural and social determinants presented at the 7th Annual Vaccine Acceptance Meeting

International Journal of Infectious Diseases
Volume 105 p1-784
https://www.ijidonline.com/current

 

Original Reports
Increasing vaccine acceptance using evidence-based approaches and policies: Insights from research on behavioural and social determinants presented at the 7th Annual Vaccine Acceptance Meeting
Katie Attwell, Cornelia Betsch, Eve Dubé, …L. Suzanne Suggs, Valentina Picot, Angus Thomson
Published online: February 09, 2021
p188-193

HPV Vaccination Among Young Adults in the US

JAMA
April 27, 2021, Vol 325, No. 16, Pages 1593-1688
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
HPV Vaccination Among Young Adults in the US
Michelle M. Chen, MD, MHS; Nicole Mott, BS; Sarah J. Clark, MPH; et al.
JAMA. 2021;325(16):1673-1674. doi:10.1001/jama.2021.0725
This study uses data from the 2010-2018 National Health Interview Survey to characterize trends in human papillomavirus (HPV) vaccination rates, ages at vaccination, and numbers of doses received among young adults in the US between 2010 and 2018.

First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff

JAMA
April 27, 2021, Vol 325, No. 16, Pages 1593-1688
https://jamanetwork.com/journals/jama/currentissue

 

JAMA Insights
First-Dose COVID-19 Vaccination Coverage Among Skilled Nursing Facility Residents and Staff
Radhika Gharpure, DVM, MPH; Anita Patel, PharmD, MS; Ruth Link-Gelles, PhD, MPH
has active quiz has audio
JAMA. 2021;325(16):1670-1671. doi:10.1001/jama.2021.2352
This JAMA Insights review from CDC COVID-19 Response team members presents data on the number of long-term care facilities and the numbers of residents and staff of those facilities who received first-dose vaccination through mid-January 2021 under the agency’s public-private partnership with CVS, Walgreens, and Managed Health Care Associates.

Online medication purchasing during the Covid-19 pandemic: potential risks to patient safety and the urgent need to develop more rigorous controls for purchasing online medications, a pilot study from the United Arab Emirates

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 1 May 2021]

 

Online medication purchasing during the Covid-19 pandemic: potential risks to patient safety and the urgent need to develop more rigorous controls for purchasing online medications, a pilot study from the United Arab Emirates
Since the WHO announced that Covid-19 had become a global pandemic, online pharmacies have emerged as an extremely popular way to purchase medication due to the quarantine measures introduced by numerous count…
Authors: Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Naseem Mohammed Abdulla, Faris El-Dahiyat, Maimona Jairoun, Saleh Karamah AL-Tamimi and Zaheer-Ud-Din Babar
Citation: Journal of Pharmaceutical Policy and Practice 2021 14:38
Content type: Research
Published on: 30 April 2021

An Ace Up Our Sleeves: The COVID-19 Vaccine Rollout Revealed Our Strengths and Our Neglected Public Health Infrastructure

Journal of Public Health Management & Practice
May/June 2021 – Volume 27 – Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Editorials
An Ace Up Our Sleeves: The COVID-19 Vaccine Rollout Revealed Our Strengths and Our Neglected Public Health Infrastructure
Pierce, Heather H.
Journal of Public Health Management and Practice. 27(3):223-225, May/June 2021.

Maintaining a Focus on Health Equity During the COVID-19 Vaccine Rollout

Journal of Public Health Management & Practice
May/June 2021 – Volume 27 – Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx

 

Commentary
Maintaining a Focus on Health Equity During the COVID-19 Vaccine Rollout
Martin, Erika G.; Birkhead, Guthrie S.; Holtgrave, David R.
Journal of Public Health Management and Practice. 27(3):226-228, May/June 2021.

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

The Lancet
May 01, 2021 Volume 397 Number 10285 p1597-1682, e11
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Eleftheria Vasileiou, et al
Open Access
Summary
Background
The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programmes in the UK and several other countries. Studying the real-world effects of these vaccines is an urgent requirement. The aim of our study was to investigate the association between the mass roll-out of the first doses of these COVID-19 vaccines and hospital admissions for COVID-19.
Findings
Between Dec 8, 2020, and Feb 22, 2021, a total of 1 331 993 people were vaccinated over the study period. The mean age of those vaccinated was 65·0 years (SD 16·2). The first dose of the BNT162b2 mRNA vaccine was associated with a vaccine effect of 91% (95% CI 85–94) for reduced COVID-19 hospital admission at 28–34 days post-vaccination. Vaccine effect at the same time interval for the ChAdOx1 vaccine was 88% (95% CI 75–94). Results of combined vaccine effects against hospital admission due to COVID-19 were similar when restricting the analysis to those aged 80 years and older (83%, 95% CI 72–89 at 28–34 days post-vaccination).
Interpretation
Mass roll-out of the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines was associated with substantial reductions in the risk of hospital admission due to COVID-19 in Scotland. There remains the possibility that some of the observed effects might have been due to residual confounding.
Funding
UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK.

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

The Lancet
May 01, 2021 Volume 397 Number 10285 p1597-1682, e11
https://www.thelancet.com/journals/lancet/issue/current

 

Clinical Picture
Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination
Antonios Bayas, Martina Menacher, Monika Christ, Lars Behrens, Andreas Rank, Markus Naumann

Can technology increase COVID-19 vaccination rates?

Lancet Digital Health
Apr 2021 Volume 3 Number 4 e204-e273
https://www.thelancet.com/journals/landig/issue/current

 

Editorial
Can technology increase COVID-19 vaccination rates?
The Lancet Digital Health
… To manage the wealth of data from adverse events tracking, the MHRA have awarded £1·5 million to develop AI that can identify genuine COVID-19 vaccine adverse effects. While experts have applauded the MHRA’s forward thinking approach, development of AI based on limited self-reported public data and electronic health records that are subject to historic and systemic bias must be validated on data from minority and other at risk populations to maintain trust within these communities.
To combat bias in datasets and algorithms, transparent auditing of clinical AI tools is essential to accurately communicate results to the public for greater vaccine uptake. As the UK and the USA pass the milestones of 20 million and 100 million people (respectively) vaccinated against COVID-19, associated data must be made transparent and accessible. Datasets such as the England and Wales COVID-19 vaccination datasets, which are available upon request to researchers, are critical to communicate real-world effectiveness of the vaccine to the public.
President Biden has recently pledged over $500 million in additional funds to address vaccine uptake in the USA. This funding must be spent on establishing transparent COVID-19 vaccine data to aid informed public decisions. Technology can help monitor progress of vaccine programmes, but it will not be enough to establish trust among the public, especially among those most at risk.

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial

Lancet Infectious Diseases
May 2021 Volume 21 Number 5 p579-742, e110-e140
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
Kimberly Davis, et al

The Use and Misuse of Mathematical Modeling for Infectious Disease Policymaking: Lessons for the COVID-19 Pandemic

Medical Decision Making (MDM)
Volume 41 Issue 4, May 2021
http://mdm.sagepub.com/content/current

 

Review
The Use and Misuse of Mathematical Modeling for Infectious Disease Policymaking: Lessons for the COVID-19 Pandemic
Lyndon P. James, Joshua A. Salomon, Caroline O. Buckee, Nicolas A. Menzies
First Published February 3, 2021; pp. 379–385

COVID vaccines: time to confront anti-vax aggression

Nature
Volume 592 Issue 7856, 29 April 2021
https://www.nature.com/nature/volumes/592/issues/7856

 

World View | 27 April 2021
COVID vaccines: time to confront anti-vax aggression
Halting the spread of the coronavirus will require a high-level counteroffensive against new destructive forces.
Peter Hotez
Nearly one billion COVID-19 vaccine doses have been delivered in less than six months, but anti-vaccine disinformation and targeted attacks on scientists are undermining progress. These threats must be confronted directly, and the authority and expertise of the health community alone aren’t enough to do this.

Even before the pandemic, I had a front-row seat to all of this. I have co-led efforts to develop vaccines in programmes, including a COVID-19 vaccine currently being tested in India. I also have an adult daughter with autism; my 2018 book, Vaccines Did Not Cause Rachel’s Autism, became a dog whistle for anti-vaccine activists.

The World Health Organization recognized vaccine hesitancy as a top threat to global health before the pandemic. As COVID-19 vaccines moved through development, the public-health communities anticipated considerable vaccine hesitancy. Teams of experts, including me, began meeting regularly online to discuss how best to amplify evidence-based messages, deliver public-service announcements and address concerns around COVID-19 immunization.

I experienced sinking feelings during our Zoom calls. Although certainly worthwhile, I knew that messaging alone would be inadequate. We’d already seen this inadequacy in our efforts to prevent measles from returning to the United States and Europe in 2019, and to bolster vaccination rates for human papillomavirus to prevent cervical and other cancers. With COVID-19, our pro-vaccine messages would be drops in a vast sea of misinformation, much of it poured in deliberately by anti-vaccine forces.

I have a long-standing disagreement with many of my US public-health colleagues. I admire their commitment to disease prevention, but when I ask for a more direct way to counter anti-vaccine aggression, I’m told, “that’s not our approach; confrontation gives them a platform and oxygen.” In my opinion, this attitude reflects a time when we had dial-up modems. Today, the anti-vaccine empire has hundreds of websites and perhaps 58 million followers on social media. The bad guys are winning, in part because health agencies either underestimate or deny the reach of anti-science forces, and are ill-equipped to counter it.

Investigations by the US State Department and the UK Foreign Office have described how Russian intelligence organizations seek to discredit Western COVID-19 vaccines. One campaign implies that it could turn people into monkeys. This builds on a longer, well-documented history of Russia-sponsored disinformation, presumably to destabilize the United States and other democratic countries. The administration of US President Joe Biden has warned Russian media groups to halt their anti-vaccine aggression, and announced sanctions tied to disinformation and other behaviour, but we need much more.

The United States hosts the world’s largest and best-organized anti-vaccine groups. According to the London-based Center for Countering Digital Hate, these are influential groups, not a spontaneous grass-roots movement. Many far-right extremist groups that spread false information about last year’s US presidential election are doing the same about vaccines. Anti-vaccine groups also target Black communities; an anti-vaccine documentary released in March vilifies COVID-19 vaccine testing among African Americans, calling it “medical racism”.

Global anti-vaccine messaging around the adenovirus vaccines means that more people will die and the pandemic will be prolonged. Extremely rare but life-threatening blood clots caused the United States to pause roll-out of the Johnson & Johnson vaccine, and many European nations have stopped or restricted use of the Oxford–AstraZeneca vaccine for similar reasons. However, those regions have other vaccine options, which is not the case for many countries. In March, Cameroon and the Democratic Republic of the Congo halted use of the Oxford–AstraZeneca vaccine, and the African Union has stopped procurement.

Many people in Africa are tapping into anti-vaccine messaging. A rumour-tracking program from the analytics company Novetta in McLean, Virginia, finds that Russia specifically targets African countries to discredit Western vaccines in favour of its own Sputnik V. US-based anti-vaccine groups invoke colonialism and eugenics. Now, tens of thousands of vaccine doses are going unused. Anti-vaccine disinformation has turned reasonable questions and concerns over rare side effects into conspiracy worries, exaggerated fears, and outrage at being treated like ‘guinea pigs’.

Accurate, targeted counter-messaging from the global health community is important but insufficient, as is public pressure on social-media companies. The United Nations and the highest levels of governments must take direct, even confrontational, approaches with Russia, and move to dismantle anti-vaccine groups in the United States.

Efforts must expand into the realm of cyber security, law enforcement, public education and international relations. A high-level inter-agency task force reporting to the UN secretary-general could assess the full impact of anti-vaccine aggression, and propose tough, balanced measures. The task force should include experts who have tackled complex global threats such as terrorism, cyber attacks and nuclear armament, because anti-science is now approaching similar levels of peril. It is becoming increasingly clear that advancing immunization requires a counteroffensive.

The influence of evolutionary history on human health and disease

Nature Reviews Genetics
Volume 22 Issue 5, May 2021
https://www.nature.com/nrg/volumes/22/issues/5

 

Review Article | 06 January 2021
The influence of evolutionary history on human health and disease
Our evolutionary history has resulted in highly complex and sophisticated human physiology. Yet evolutionary footprints have also left us prone to diseases. In this Review, the authors discuss how events from the earliest history of life on Earth through to modern human evolution influence many disease traits and outcomes. They describe how an understanding and application of evolutionary frameworks can inform precision medicine initiatives.
Mary Lauren Benton, Abin Abraham, John A. Capra

African genetic diversity and adaptation inform a precision medicine agenda

Nature Reviews Genetics
Volume 22 Issue 5, May 2021
https://www.nature.com/nrg/volumes/22/issues/5

 

Review Article | 11 January 2021
African genetic diversity and adaptation inform a precision medicine agenda
Africa is a continent with deep evolutionary history, which has implications for the genetic underpinnings of disease. In this Review, the authors discuss how genetic features of African populations provide both challenges and opportunities for understanding disease genetics in Africa. They describe how this genetic knowledge — combined with initiatives including capacity-building, data sharing and increased representation of African genomes in genetic variation databases — can be leveraged towards achieving precision medicine approaches in African healthcare.
Luisa Pereira, Leon Mutesa, Michèle Ramsay

Vaccination plus Decarceration — Stopping Covid-19 in Jails and Prisons

New England Journal of Medicine
April 29, 2021 Vol. 384 No. 17
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
Vaccination plus Decarceration — Stopping Covid-19 in Jails and Prisons
Benjamin A. Barsky, J.D., M.B.E., Eric Reinhart, B.A., Paul Farmer, M.D., Ph.D., and Salmaan Keshavjee, M.D., Ph.D.
… Stopping the epidemic in jails and prisons is vital for protecting staff and incarcerated people; it is also critical for curbing the spread of Covid-19 into surrounding communities, especially Black and Latinx communities that are disproportionately affected by jail- and prison-linked coronavirus spread.1 Furthermore, as we become aware of an increasing range of SARS-CoV-2 variants, we face greater urgency to disrupt the ideal environment that current carceral conditions provide for viral mutations that could undermine the efficacy of available vaccines and threaten health far beyond American borders.
Vaccination of incarcerated people is important for changing this dynamic, but it is not enough. We believe that it must be coupled with large-scale decarceration to increase the real-world effectiveness of vaccination, disrupt wide-ranging viral transmission chains, and turn off the epidemiologic pump that puts the health of all at risk from mass incarceration.
Decarceration strategies can guide decisions made by a range of actors who wield power to change current conditions, including federal and state legislators, state and local law enforcement, prosecutors, judges, mayors, governors, the U.S. attorney general, and the president of the United States. We believe the medical community has a parallel responsibility to ensure that science is heard and applied. On the grounds of scientific evidence and our ethical responsibility to protect the vulnerable and the public at large, we can use our influence to demand that policymakers implement decarceration alongside priority vaccination in jails and prisons.